612 related articles for article (PubMed ID: 32151314)
1. Fatal amyloid formation in a patient's antibody light chain is caused by a single point mutation.
Kazman P; Vielberg MT; Pulido Cendales MD; Hunziger L; Weber B; Hegenbart U; Zacharias M; Köhler R; Schönland S; Groll M; Buchner J
Elife; 2020 Mar; 9():. PubMed ID: 32151314
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanism of amyloidogenic mutations in hypervariable regions of antibody light chains.
Rottenaicher GJ; Weber B; Rührnößl F; Kazman P; Absmeier RM; Hitzenberger M; Zacharias M; Buchner J
J Biol Chem; 2021; 296():100334. PubMed ID: 33508322
[TBL] [Abstract][Full Text] [Related]
3. A constant domain mutation in a patient-derived antibody light chain reveals principles of AL amyloidosis.
Rottenaicher GJ; Absmeier RM; Meier L; Zacharias M; Buchner J
Commun Biol; 2023 Feb; 6(1):209. PubMed ID: 36823438
[TBL] [Abstract][Full Text] [Related]
4. Domain Interactions Determine the Amyloidogenicity of Antibody Light Chain Mutants.
Weber B; Hora M; Kazman P; Pradhan T; Rührnößl F; Reif B; Buchner J
J Mol Biol; 2020 Nov; 432(23):6187-6199. PubMed ID: 33058870
[TBL] [Abstract][Full Text] [Related]
5. Light chain amyloidosis - current findings and future prospects.
Baden EM; Sikkink LA; Ramirez-Alvarado M
Curr Protein Pept Sci; 2009 Oct; 10(5):500-508. PubMed ID: 19538145
[TBL] [Abstract][Full Text] [Related]
6. Mutations can cause light chains to be too stable or too unstable to form amyloid fibrils.
Marin-Argany M; Güell-Bosch J; Blancas-Mejía LM; Villegas S; Ramirez-Alvarado M
Protein Sci; 2015 Nov; 24(11):1829-40. PubMed ID: 26300552
[TBL] [Abstract][Full Text] [Related]
7. Seeded fibrils of the germline variant of human λ-III immunoglobulin light chain FOR005 have a similar core as patient fibrils with reduced stability.
Pradhan T; Annamalai K; Sarkar R; Huhn S; Hegenbart U; Schönland S; Fändrich M; Reif B
J Biol Chem; 2020 Dec; 295(52):18474-18484. PubMed ID: 33093170
[TBL] [Abstract][Full Text] [Related]
8. Decreased amyloidogenicity caused by mutational modulation of surface properties of the immunoglobulin light chain BRE variable domain.
Kobayashi Y; Tsutsumi H; Abe T; Ikeda K; Tashiro Y; Unzai S; Kamikubo H; Kataoka M; Hiroaki H; Hamada D
Biochemistry; 2014 Aug; 53(31):5162-73. PubMed ID: 25062800
[TBL] [Abstract][Full Text] [Related]
9. Identification of two principal amyloid-driving segments in variable domains of Ig light chains in systemic light-chain amyloidosis.
Brumshtein B; Esswein SR; Sawaya MR; Rosenberg G; Ly AT; Landau M; Eisenberg DS
J Biol Chem; 2018 Dec; 293(51):19659-19671. PubMed ID: 30355736
[TBL] [Abstract][Full Text] [Related]
10. Mutations in specific structural regions of immunoglobulin light chains are associated with free light chain levels in patients with AL amyloidosis.
Poshusta TL; Sikkink LA; Leung N; Clark RJ; Dispenzieri A; Ramirez-Alvarado M
PLoS One; 2009; 4(4):e5169. PubMed ID: 19365555
[TBL] [Abstract][Full Text] [Related]
11. Protease-sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation.
Mazzini G; Ricagno S; Caminito S; Rognoni P; Milani P; Nuvolone M; Basset M; Foli A; Russo R; Merlini G; Palladini G; Lavatelli F
FEBS J; 2022 Jan; 289(2):494-506. PubMed ID: 34482629
[TBL] [Abstract][Full Text] [Related]
12. The Kinetic Stability of a Full-Length Antibody Light Chain Dimer Determines whether Endoproteolysis Can Release Amyloidogenic Variable Domains.
Morgan GJ; Kelly JW
J Mol Biol; 2016 Oct; 428(21):4280-4297. PubMed ID: 27569045
[TBL] [Abstract][Full Text] [Related]
13. Cryo-EM structure of a light chain-derived amyloid fibril from a patient with systemic AL amyloidosis.
Radamaker L; Lin YH; Annamalai K; Huhn S; Hegenbart U; Schönland SO; Fritz G; Schmidt M; Fändrich M
Nat Commun; 2019 Mar; 10(1):1103. PubMed ID: 30894526
[TBL] [Abstract][Full Text] [Related]
14. Kinetic control in protein folding for light chain amyloidosis and the differential effects of somatic mutations.
Blancas-Mejía LM; Tischer A; Thompson JR; Tai J; Wang L; Auton M; Ramirez-Alvarado M
J Mol Biol; 2014 Jan; 426(2):347-61. PubMed ID: 24157440
[TBL] [Abstract][Full Text] [Related]
15. Driving forces in amyloidosis: How does a light chain make a heavy heart?
Otzen DE
J Biol Chem; 2021; 296():100785. PubMed ID: 34019874
[TBL] [Abstract][Full Text] [Related]
16. Immunoglobulin light chain amyloid aggregation.
Blancas-Mejia LM; Misra P; Dick CJ; Cooper SA; Redhage KR; Bergman MR; Jordan TL; Maar K; Ramirez-Alvarado M
Chem Commun (Camb); 2018 Sep; 54(76):10664-10674. PubMed ID: 30087961
[TBL] [Abstract][Full Text] [Related]
17. The Antibody Light-Chain Linker Regulates Domain Orientation and Amyloidogenicity.
Weber B; Hora M; Kazman P; Göbl C; Camilloni C; Reif B; Buchner J
J Mol Biol; 2018 Dec; 430(24):4925-4940. PubMed ID: 30414962
[TBL] [Abstract][Full Text] [Related]
18. Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient.
Swuec P; Lavatelli F; Tasaki M; Paissoni C; Rognoni P; Maritan M; Brambilla F; Milani P; Mauri P; Camilloni C; Palladini G; Merlini G; Ricagno S; Bolognesi M
Nat Commun; 2019 Mar; 10(1):1269. PubMed ID: 30894521
[TBL] [Abstract][Full Text] [Related]
19. Solid state NMR assignments of a human λ-III immunoglobulin light chain amyloid fibril.
Pradhan T; Annamalai K; Sarkar R; Hegenbart U; Schönland S; Fändrich M; Reif B
Biomol NMR Assign; 2021 Apr; 15(1):9-16. PubMed ID: 32946005
[TBL] [Abstract][Full Text] [Related]
20. Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis.
Ward JE; Ren R; Toraldo G; Soohoo P; Guan J; O'Hara C; Jasuja R; Trinkaus-Randall V; Liao R; Connors LH; Seldin DC
Blood; 2011 Dec; 118(25):6610-7. PubMed ID: 21998211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
